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Background: Treatment guidelines provide recommendations but 
cannot account for the wide variability in patient-tumor character-
istics in individual patients. We developed an on-line interactive 
decision tool to provide expert recommendations for specific patient 
scenarios in the first-line and maintenance settings for advanced 
non–small-cell lung cancer. We sought to determine how providing 
expert feedback would influence clinical decision-making.
Method: Five lung cancer experts selected treatment for 96 differ-
ent patient cases based on patient and/or tumor-specific features. 
These data were used to develop an on-line decision tool. Participant 
physicians entered variables for their patient scenario with treatment 
choices, and then received expert treatment recommendations for 
that scenario. To determine the impact on decision-making, users 
were asked whether the expert feedback impacted their original plan.
Results: A total of 442 individual physicians, of which 88% were from 
outside the United States, entered 653 cases, with report on impact in 
389 cases. Expert feedback affected treatment choice in 73% of cases 
(23% changed and 50% confirmed decisions). For cases with epidermal 
growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase 
(ALK) fusion, all experts selected targeted therapy whereas 51% and 
58% of participants did not. Greater variability was seen between experts 
and participants for cases involving EGFR or ALK wild-type tumors. 
Participants were 2.5-fold more likely to change to expert recommended 
therapy for ALK fusions than for EGFR mutations (p = 0.017).
Conclusion: This online tool for treatment decision-making resulted 
in a positive influence on clinician’s decisions. This approach offers 
opportunities for improving quality of care and meets an educational 
need in application of new therapeutic paradigms.
Key Words: Interactive online tool, Therapeutic decision-making, 
Advanced non–small-cell lung cancer.
(J Thorac Oncol. 2015;10: 1421–1429)
The transition from empiric to evidence-based medicine has accelerated in recent years. In the case of advanced 
stage non-small cell lung cancer (NSCLC), a number of treat-
ment guidelines have been published, both within the United 
States and internationally, which are increasingly utilized by 
not only practitioners, but also institutions, governments, and 
third-party payers. These guidelines provide lists of multiple 
options for first-line and maintenance therapy for broad groups 
of patients with advanced stage NSCLC. However, guidelines 
are less useful for selecting first-line or maintenance therapy 
for individual patients, where many variables must be consid-
ered, including both tumor and patient-specific characteristics.
The importance of performance status (PS) and gender 
as prognostic and predictive factors for therapeutic outcome 
in NSCLC is well established.1 Within the last decade, specific 
histologic subtypes of NSCLC, particularly nonsquamous 
cancers, have been recognized as useful to select for treatment 
with chemotherapy, such as pemetrexed, and targeted therapy, 
such as bevacizumab.2 Most recently, knowledge of the spe-
cific molecular genotype of NSCLC, specifically activating 
mutations of the epidermal growth factor receptor (EGFR) 
gene and rearrangements of the anaplastic lymphoma kinase 
(ALK) gene, has become essential to optimizing therapy.2 
Even with these distinctions, there are often several reason-
able therapeutic options available. Thus, integration of these 
clinical, histologic, and molecular features into therapeutic 
decision-making is essential to optimize therapy.
To assist clinical oncologists in making informed treat-
ment decisions, we developed an on-line tool—an interactive 
interface designed to provide expert guidance on treatment 
choices in multiple defined patient case scenarios. This edu-
cational tool, based on 96 different patient case variations for 
first-line and maintenance therapy in advanced NSCLC, also 
explored and captured the variability in treatment decisions 
by practicing physicians in this disease setting and provided 
an interactive forum for comparison of expert and partici-
pant treatment choices. The interactive tool was constructed 
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to survey both experts and practicing oncologists about treat-
ment recommendations, using a panel of expert opinions as a 
comparator, and to serve as an educational tool for therapeutic 
decision-making. Here, we report results from 389 participant 
evaluations from a total of 653 case interactions captured with 
this on-line tool.
PATIENTS AND METHODS
This interactive program was designed to be 
accessed on-line (http://www.clinicaloptions.com/Oncology/
Treatment%20Updates/Advanced%20NSCLC%202012/
Interactive%20Tool/NSCLC.aspx) by participants who pro-
vide clinical care to patients with advanced NSCLC. The 
primary objective of the tool was to provide an interactive 
mechanism for assessing practitioner therapeutic decision-
making in a wide variety of patient case scenarios and to 
compare practitioner choices with those of an expert panel. 
Both experts and participants were instructed to assume 
that all choices were available in all case scenarios.
Five experts made first and second treatment recom-
mendations for 96 patient cases that varied based on per-
mutations of six characteristics, namely tumor histology, 
tumor mutational status (EGFR or ALK), age, PS, smok-
ing history, and patient goals (Table 1). Age of ≥70 years 
was selected as an age threshold because of its typical use 
as a definition of “elderly” in clinical trials of lung cancer 
and the fact that age 70 years represents the approximate 
median age of NSCLC patients.3 Expert decision-making 
was based on individual knowledge and experience rather 
than adherence to published guidelines. Treatment choices 
were integrated into an interactive decision support tool. 
All five experts addressed each of the 96 case scenarios 
independently, blinded from each other. The goal was to 
obtain their independent recommendations, not to reach 
consensus. There was no attempt to reconcile differences of 
opinion because one of the goals was to display both con-
currence and differences opinion between experts. The table 
of cases and expert treatment selections was entered into 
Site core, a Microsoft.NET-based web content management 
system. The content drove a custom-built workflow engine 
that leverages HTML and JavaScript to dynamically guide 
users through the process of supplying patient-tumor char-
acteristics and proposed treatment options. On the basis of 
the options chosen, users were presented with appropriate 
recommendations from experts.
The on-line tool began with a disclaimer statement stat-
ing its purpose and limitations. After acknowledging the dis-
claimer, participants were able to enter specific information 
related to six major clinical elements important for making 
therapeutic decisions using pull-down menus. Participants 
addressed case scenarios of their choosing in a tree-based for-
mat, in which the on-line clinical tool populated details of the 
corresponding clinical case based on the algorithm. Users of 
the tool entered specific patient characteristics, such as tumor 
histologic subtype and primary patient goals on a case-by-case 
basis, and then selected their therapeutic choice. All treatment 
choices were available to all participants, regardless of coun-
try of origin. Subsequently, expert recommendations for a 
case that specifically matched the user’s case were displayed. 
Users were then asked if those recommendations impacted 
their treatment decision. Expert and participant responses 
were subsequently analyzed.
Case Variations for First-Line and 
Maintenance Therapy
A total of 96 individual case variations were available 
in the on-line tool, based on matching characteristics from 
six categories, as described above and summarized in Table 1. 
Therapeutic options were divided among (a) targeted therapy, 
(b) platinum-based chemotherapy, (c) non-platinum-based 
chemotherapy, (d) unsure, and (e) none. Options under tar-
geted therapy were bevacizumab, cetuximab, erlotinib, crizo-
tinib, unsure, and none. Platinum chemotherapy were cisplatin 
versus carboplatin (paired with a non-platinum drug to form 
a chemotherapy doublet), unsure, or none. Non-platinum che-
motherapy options were paclitaxel, docetaxel, gemcitabine, 
vinorelbine, pemetrexed, and etoposide, unsure or none.
Statistical Analysis
Physician characteristics were summarized descrip-
tively as number and proportion from outside United States, 
both overall and for participants who provided one or more 
evaluations of the on-line tool. A generalized Kappa statis-
tics method was employed to calculate agreement among 
experts, compared with that expected by chance, across the 
96 patient-description combinations as recommended by 
Agresti,4 implemented in SAS. Case characteristics were sum-
marized descriptively as observed case-wise frequencies and 
proportions. We estimated population probability of changing 
treatment plan with 95% confidence interval (CI) adjusted for 
within-physician clustering of patients. We examined whether 
the odds of modifying the care plan for a case were affected 
by patient, physician, or tumor characteristics, using a gener-
alized linear model approach with logistic link and binomial 
error structure, adjusted for within-physician clustering. All 
analyses were carried out in SAS.
TABLE 1.  Case Scenario Variable
Tumor Histology Mutation Status Age (years) Zubrod PS Smoking History Desired Outcome
Non–squamous EGFR+/ALK− <70 0, 1 No/former light smoker Response/survival
Squamous EGFR−/ALK+ ≥70 2 Former heavy/current 
smoker
QoL/low risk of AEs
EGFR−/ALK−
Ninety-six case variations created based on these variables.
PS, performance status;EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; AEs, toxicities from therapy.
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Validation of Expert Recommendations
Expert recommendations consisted not only of a treat/
do-not-treat for each component of first-line and maintenance 
treatment, but also of a choice for specific drugs. An agree-
ment algorithm was constructed as follows: we characterized 
agreement for each of the six questions as perfect consensus 
(all five experts recommended exactly the same choice), near-
perfect consensus (four of the five recommended exactly the 
same choice), good consensus (at least four of the five recom-
mended that class of treatment but there was disagreement on 
the specific therapy), or disagreement (the experts had a 3–2 
split on treatment). The six questions pertain to expert recom-
mendations in selecting either targeted therapy, platinum che-
motherapy, or non-platinum based chemotherapy as first-line 
treatment and maintenance treatment.
RESULTS
Demographics of Participants
A total of 442 physicians entered 653 cases from 
between March 2012 and July 2012 with the majority of cases 
entered within 1 month of on-line posting of the tool; 273 
participants also recorded whether the on-line tool influenced 
their decision, for a total of 389 cases. Overall, 12% of the 
participating physicians were from the United States, whereas 
88% were practitioners outside the United States. Of the par-
ticipants, 82% recorded influence of the on-line tool in their 
decision-making.
The overall distribution of the clinical characteristics of 
the 653 unique cases is summarized in Table 2. The major-
ity of case scenarios entered (74%) were for non–squamous 
histology. The distribution of the oncogene status of the phy-
sician-entered cases was 31% for EGFR mutation only, 9% 
for ALK-fusion only, and 59% without these alterations (i.e., 
were wild type for both EGFR and ALK). A majority of the 
cases (79%) were for patients younger than 70 years old. A 
similar distribution of entered cases was seen for Zubrod PS 
with 86% having a PS of 0 and 1 and 14% of the cases having 
a PS of 2. Nonsmokers or former light smokers comprised 
43% of the cases versus 57% reported as former heavy or cur-
rent smokers. Finally, the desired outcome and goals of treat-
ment in most cases (76%) were improved tumor response rate 
or survival, with 24% favoring a better quality of life (QoL) 
or fewer treatment-related adverse events. Percentages were 
similar for the subset of cases for which physicians reported 
the influence of the on-line tool (Table 2).
FIGURE 1.  Choice of first-line therapy: 
(A) nonsquamous (EGFR−/ALK−) and (B) 
squamous (EGFR−/ALK−).
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Experts’ Responses
First-line therapy
Five thoracic medical oncology experts participated in 
the process, each completing treatment selections for all 96 
possible case scenarios, and each blinded from the opinions 
of the other experts. The experts were largely in agreement 
for cases that had actionable genetic alterations in the tumor. 
In EGFR mutation-positive cases, all of the experts (100%) 
agreed with using erlotinib-based therapy in the frontline 
setting. Four of five of the experts (80%) agreed on using 
first-line therapy with erlotinib alone, whereas three of five 
(60%) agreed with maintenance therapy with single-agent 
erlotinib. This recommendation was independent of tumor 
histology, age, PS, smoking history, or desired outcome. One 
of the experts chose erlotinib plus doublet chemotherapy as 
first-line treatment and maintenance therapy with erlotinib 
plus chemotherapy, depending on the specific case scenario 
for tumor histology, PS, and desired outcome. Similarly, in 
ALK fusion-positive cases, all experts (100%) chose crizo-
tinib-based therapy in the frontline setting with four of five 
experts choosing single-agent crizotinib as both first-line 
therapy and maintenance therapy independent of patient 
characteristics. One expert chose crizotinib plus chemother-
apy as both first-line and maintenance therapy in nonsqua-
mous cell tumor histology and PS 0 and 1 patients. There 
was greater variability in regimens selected by the experts 
for patients with cancers without an EGFR mutation or ALK 
fusion, where factors such as PS, age, and patient desired 
outcomes changed the choice of treatment between various 
experts (Fig. 1A and B).
Maintenance therapy
When experts offered maintenance chemotherapy, it 
tended to associate closely with age, PS, and primary patient 
objective. Experts tended to offer maintenance therapy for 
patients whose desired outcome was higher response rate and 
increased chance of survival in the nonsquamous and EGFR 
mutation/ALK fusion negative cases with four of five experts 
recommending maintenance therapy in patients <70 years of 
age regardless of PS or in patients ≥70 with a PS of 2. Only 
two of five experts offered maintenance therapy for patients 
with squamous cancers (EGFR mutation and ALK fusion neg-
ative) independent of age, PS, and patient objective/desired 
outcome.
Validation of experts’ advice
There was generally excellent agreement among the 
experts for all six questions pertaining to treatment selec-
tion using targeted, platinum, and non-platinum therapy 
in both first-line and maintenance therapy. Either perfect 
agreement among experts or near-perfect consensus (four 
of the five agreeing exactly) was observed for 81–100% 
of the 96 case scenarios, with greatest agreement on rec-
ommendation for first-line targeted therapy and lowest for 
platinum-based therapy either for first-line or maintenance. 
In almost all the remaining cases, at least four of the five 
agreed on the decision to treat or not to treat, with some 
disagreement on which treatment to choose. In 10 cases, 
there was a 3:2 split on the question of whether to use non-
platinum-based maintenance therapy, but general consensus 
on the other questions. For two cases, there was a 3:2 split 
not only on non-platinum-based maintenance therapy but 
also on whether to use targeted therapy, both first-line and 
maintenance.
Thus, overall there was consensus among experts in 94 
of the 96 case scenarios for all treatment questions except for 
platinum maintenance therapy, with an average of 90% having 
perfect agreement or near-perfect agreement (four or five of 
five experts). For non-platinum maintenance therapy, agree-
ment was excellent (perfect and near perfect) in 82 of the 96 
cases.
Generalized Kappa statistics showed agreement exceed-
ing chance alone for all components of frontline and mainte-
nance therapy, with the best agreement for whether targeted 
therapy should be used (0.86 frontline, 0.81 maintenance) and 
platinum (0.61 frontline, 1.0 maintenance.) Experts agreed 
more than by chance on non-platinum based chemotherapy, 
but less strikingly (0.39 frontline, 0.37 maintenance)
Physician Participants’ Responses
Choice of first-line therapy in regard to the EGFR  
mutation/ALK fusion status
Physician participants entered 189 EGFR mutation-pos-
itive cases. For these patients, participants varied considerably 
in selection of frontline EGFR tyrosine kinase inhibitor-based 
therapy, in contrast to the expert panel (49% of participants 
vs. 100% of experts chose erlotinib; Fig. 2A). Moreover, par-
ticipants more frequently selected frontline chemotherapy for 
TABLE 2.  Characteristics of Patient Cases Entered by 
Physician Participants
Case Characteristic
Number (%) of 653 
Total Cases
Number (%) of 389 
Cases in Evaluation 
Subsample
Tumor histology
  Non–squamous 483 (74) 293 (75)
  Squamous 170 (26) 96 (25)
Mutational status
  EGFR+/ALK− 204 (31) 125 (32)
  EGFR−/ALK+ 62 (9) 33 (8)
  EGFR−/ALK− 387 (59) 231(59)
Age
  <70 yrs 519 (79) 311 (80)
  ≥70 yrs 134 (21) 78 (20)
Zubrod PS
  0 or 1 562 (86) 332 (85)
  2 91 (14) 57 (15)
Smoking history
  No/former light 281 (43) 174 (45)
  Former heavy/current 372 (57) 215 (55)
Treatment goals
  Improved RR, survival 486 (76) 296 (76)
  Better QOL 167 (24) 93 (24)
PS, performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic 
lymphoma kinase; RR, response rate; QoL, quality of life.
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this group of patients (56% of participants vs. 20% of experts; 
Fig. 2A). Another 21% of the participating physicians were 
initially unsure of what targeted therapy to choose, and 14% 
were unsure about the use of chemotherapy in the setting of 
EGFR mutation-positive cases.
Physician participants entered 55 ALK fusion-positive 
case scenarios. Fewer participants (42%) selected crizotinib 
when compared with the experts who all selected crizotinib 
(100%; Fig. 2B). Again, in these patient scenarios, partici-
pants selected chemotherapy more often as first-line treatment 
(68% vs. 20%; Fig. 2B). Similar to the results seen with EGFR 
mutation-positive cases, 24% of the participating physicians 
were initially unsure of what targeted therapy to choose, and 
16% were unsure about the use of chemotherapy in the setting 
of ALK fusion-positive cases. Among the 96 case scenarios, 
81% of the non-US participants chose to proceed with treat-
ment selection. Among this group, approximately 42% of par-
ticipants elected targeted therapy using crizotinib.
In the 244 case scenarios with nonsquamous histol-
ogy (EGFR and ALK wild type), participants tended to use a 
broader range of first-line targeted therapy and chemotherapy 
compared with the experts (Fig. 1A): 32% used bevacizumab 
and 5% used erlotinib, whereas 16% were unsure about the 
use of targeted therapy for this group of patients. In contrast, 
80% of the experts did not use targeted therapy and showed 
a large preference for chemotherapy with pemetrexed (94%) 
and carboplatin (88%) in this setting. Lastly, 121 case sce-
narios fell into the squamous histology category (also EGFR 
and ALK wild type; Fig. 1B). In this setting, there was also 
a diversity of first-line targeted therapy and chemotherapy 
selected by the participating physicians with 19% and 8% 
being unsure about the choice of targeted therapy and che-
motherapy, respectively. Notably, participants rarely selected 
contraindicated agents for squamous histology (such as beva-
cizumab [7%] or pemetrexed [3%]) with a predilection to use 
a cisplatin-based regimen.
Impact on ultimate treatment choice
Data from 273 physicians who reported impact of expert 
feedback on a total of 389 cases showed that treatment deci-
sion was changed in to reflect expert opinion in 23% of cases 
(95% CI, 19–27%, adjusted for multiple cases per physician), 
reflecting a positive influence on clinician treatment decision-
making. An additional 50% agreed initially and reported 
that experts confirmed their treatment choices. Physician 
responses were summarized descriptively by calculating the 
FIGURE 2.  Choice of first-line therapy: 
(A) EGFR mutation positive and (B) ALK 
fusion positive.
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proportion of cases with specific characteristics and the pro-
portion of cases for which the on-line tool led to a change, 
confirmation, or disagreement by the physician user (Fig. 3). 
We further examined what features of the case were most 
likely to be associated with a change in treatment to conform 
with expert opinion, and found that ALK mutations were 2.5-
fold more likely than EGFR mutations to be associated with 
a change to recommended therapy (95% CI, 1.18–5.49 fold, 
p = 0.017), whereas wild-type tumors were no more likely 
than EGFR+ to lead to treatment changes. Tumor histology, 
treatment goal, age and PS status of patient, smoking history, 
and nationality of physician participant were not associated 
with differences in likelihood of changing treatment (Table 3). 
The self-reported responses to expert opinion on treatment for 
ALK-positive tumors were very similar for foreign and US 
physicians. Although the numbers of US physicians were 
small, the observed frequencies were very similar between the 
two groups, suggesting that the absence of statistical signifi-
cance was not simply a result of sample size.
DISCUSSION
Significant advances in the treatment of advanced stage 
NSCLC have been made, driven by availability of new drugs, 
recognition of drug-specific implications of histologic subtyp-
ing, and even more importantly, by discovery of molecular 
subsets of NSCLC, currently best defined by EGFR mutation 
and ALK fusion.5–8 Contraindications in patients with squa-
mous cell cancers for bevacizumab because of toxicity issues 
and for pemetrexed because of reduced efficacy, stand as prime 
examples for the importance of histology-directed therapy in 
advanced NSCLC. Although initial data support the increased 
efficacy of EGFR tyrosine kinase inhibitors in patients with 
adenocarcinomas, the discovery of EGFR activating muta-
tions in 2004 provides an underlying biologic explanation for 
histology-divergent activity of these agents.5 Moreover, tri-
als, such as IPASS, have shown that clinical-pathologic char-
acteristics such as younger age, never-smoking status, and 
adenocarcinoma subtype are insufficient for treatment deci-
sion-making when compared with mutation status.6–8
More recently, patients with cancers positive for the 
EML4-ALK rearrangement, observed almost exclusively in 
the adenocarcinoma subtype of NSCLC, have been found to 
be highly responsive to crizotinib,9 a potent and relatively spe-
cific ALK inhibitor.5,10 Thus, with increasing recognition of the 
molecular heterogeneity of NSCLC and the emergence of per-
sonalized therapy for patients with advanced disease, molecu-
lar and genomic testing in addition to conventional pathology 
has become a central focus.11 The recent guidelines from 
International Association for the Study of Lung Cancer rein-
force the importance of testing for EGFR mutations and ALK 
fusions to guide patient selection for therapy with an EGFR or 
ALK inhibitor, respectively, in patients with advanced stage 
adenocarcinoma, regardless of sex, race, smoking history, or 
other clinical risk factors, and to prioritize EGFR and ALK 
testing over other molecular predictive tests.
Further complicating therapeutic decision-making in 
advanced stage NSCLC is the advent of maintenance therapy. 
In particular, pemetrexed has been demonstrated to improve 
progression-free survival and overall survival, when employed 
after first-line platinum-based chemotherapy in patients with 
initial response or disease control. Other agents, such as 
docetaxel and gemcitabine, have shown activity in this setting 
as well.2,12,13
How to interpret the large number of recent clinical 
trials in first-line therapy/maintenance therapy of advanced 
NSCLC, including the increasingly complex landscape cre-
ated by molecular testing, is a daunting task for the practicing 
oncologist, especially when placed into context for an indi-
vidual patient. Thus, there continues to be a need for new and 
easily accessible educational tools to assist in this transition 
from empiric to histology and molecular-based therapy. We 
postulate that integrating expert opinion into this educational 
process using a relatively simple interactive tool could be of 
additional assistance in understanding various case scenarios 
and formulating treatment plans.
Here, we report results of an interactive on-line tool 
that matched expert opinion with participant responses with 
respect to specific NSCLC case scenarios. This analysis high-
lights clinical practice gaps between experts and participants 
that were present during the time of the on-line tool’s imple-
mentation in 2012. This gap existed irrespective of whether 
the participants were US-based or not (Fig. 3), reflecting the 
value of this tool in identifying areas of focus for continuing 
medical education and quality improvement initiatives on an 
international basis.
Furthermore, this on-line tool can be adapted as 
needed to help clinicians in continuous acquisition of knowl-
edge essential to understanding and applying many consen-
sus guidelines currently in place.14 However, in this era of 
genomic and molecular profiling, it is increasingly difficult 
to translate guidelines into individual patient care. Often, 
the patient sitting in the oncologist’s office just does not fit 
into the guidelines because of a myriad of patient and tumor-
related variables. In addition to examining ways of streamlin-
ing guidelines themselves, interactive tools can serve both an 
educational purpose and a more practical one by translating 
FIGURE 3.  Physician Responses: did this tool 
affect (change) your treatment choice? This 
optional question had a response in 389 of 
653 physician-submitted cases.
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guidelines into direct patient care.15 Equally importantly, the 
other intent of this interactive tool was to survey both experts 
and practicing physicians about treatment recommendation. 
Clinical parameters were selected in part to see if there was 
bias in some scenarios, such as altering recommendations 
based on smoking status or age. The fact that there were few 
differences in recommendations was accurately reflected in 
the survey results. Finally, such a tool has the potential for 
use in “performance improvement continuing medical educa-
tion” modules that attempt to measure the impact of an edu-
cational intervention on actual physician practice and patient 
outcomes.
The on-line tool is not designed to provide an expected 
prognosis, and potential risk associated with each regimen can 
affect the selection of the participant physicians. However, 
unlike adjuvant on-line for breast cancer for example, which 
is used to support in to selecting whether to recommend cyto-
toxic treatment or not, the on-line tool for advance NSCLC, 
serves as an education tool for the participant physicians in 
providing expert guidance to choosing the most optimal regi-
men for patients and promoting personalized cancer therapy. 
In this on-line tool, the expected prognosis and potential risks 
to each treatment modality were not incorporated and not 
intended as the purpose of the on-line tool.
This work has several limitations, however. First, it is 
sensitive to selection bias: participants may be those who 
are less informed of the current status of care and are there-
fore seeking guidance from the on-line tool. In addition, the 
expert panel is small and therefore may not be representa-
tive of a broader group of experts in the treatment of patients 
with advanced NSCLC. Second, inasmuch as82% of the par-
ticipants were international, it is possible that variations in 
regional drug availability at the time of participation or reim-
bursement issues may have influenced participants’ responses 
on a regional basis, leading to divergence from the expert pan-
el’s recommendations. The impact of country of origin of the 
experts was considered in regression models, and there was 
no impact on likelihood of changing recommendation. The 
number of cases for specific scenarios was too small to assess 
whether likelihood of changing varied in a specific scenario 
or case type according to country of origin of the physi-
cian. Nevertheless, the tool was designed such that all treat-
ment choices were available to all experts and participants, 
regardless of country of origin. Third, the use of physician 
self-report in this interactive tool is a limitation and is subjec-
tive to response bias, which can have a large impact on the 
validity of the tool. Nevertheless, prior studies have reported 
that the effect of response bias in this context is actually very 
small, thus likely having little to no impact toward changing 
the responses of participants16,17 and does not undermine the 
benefit of the interactive tool, which was primarily designed 
to serve both a survey purpose and an educational purpose.
Discordance between experts and participants’ use of 
crizotinib in the front-line setting was notable. The US Food 
and Drug Administration granted approval of crizotinib in 
August 2011 based on the phases I and II trial data from 
PROFILE 1005.18 In Europe, European Medicines Agency 
approved crizotinib for ALK-positive patients in 2012, without 
specifying the type of test used for determining the positivity. 
In chemotherapy-pretreated patients with metastatic NSCLC 
and ALK positivity by an FDA-approved test, crizotinib was 
nevertheless approved without restriction to line of therapy 
(first, second, third, etc.) in the United States. On the contrary, 
in Europe, crizotinib was approved only in chemotherapy-
pretreated patients.19 Because both experts and participants 
were instructed to assume that all options were available in all 
case scenarios, the expert panel was perhaps more proactive in 
early adoption of crizotinib in the first-line setting.
Despite a large number of treatment options provided 
by the tool, there was consensus among the experts in for 
94 of the 96 case scenarios, with an average of 90% having 
perfect agreement or near-perfect agreement (four or five of 
five experts). On a similar note, agreement among the expert 
panel was excellent (perfect and near perfect) in 82 of the 96 
cases seen for non-platinum maintenance therapy. This degree 
of agreement among the experts’ recommendations provides 
support for the kappa statistical analysis. The expert results 
were presented both individually and as summary of the five 
opinions in a blinded fashion with the goal of displaying both 
concurrence and differences of opinion. There was no attempt 
TABLE 3.  Estimated Impact of Tumor, Patient, and Physician Characteristics on the Odds of Changing Treatment Plan to 
Follow Expert Advice
Predictor
Estimated Fold Effect on Odds of 
Change in Treatment 95% Confidence Interval P Value
Histology = squamous 0.56 0.30–1.03 0.062
Mutational status
  EGFR+/ALK− (reference) 2.54 1.18–5.49 0.017
  EGFR−/ALK+ 1.13 0.67–1.92 0.65
Treatment goal = QOL 1.09 0.52–1.61 0.77
Patient age 70 or older 0.63 0.33–1.21 0.16
Zubrod PS = 2 0.90 0.45–1.78 0.76
Current or former heavy smoker 1.08 0.61–1.67 0.88
Participant has US origin 1.33 0.71–2.51 0.37
Based on generalized linear models for 273 physicians reporting on 389 cases, one predictor at a time.
PS, performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; QoL, quality of life.
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made to resolve disagreements among the experts or reach a 
consensus. The intent of this interactive tool was to survey 
practice patterns of experts and practicing physician and to 
serve an educational purpose rather than to determine adher-
ence to guidelines and evidence based recommendations.
Another point worthy of discussion is that changing 
the smoking status or age of the patient had almost no effect 
on expert recommendations. This is in agreement with current 
guidelines that elderly fit patients and smokers can still benefit 
from standard of care therapies for NSCLC, and that therapeu-
tic options should not be curtailed. Indeed, guidelines recom-
mend molecular testing in all patients with an adenocarcinoma 
component, regardless of age or smoking status. By compari-
son, PS and co-morbidities are typically of greater importance 
in therapeutic decision-making. Thus, our findings are generally 
in agreement with current guidelines. Likewise, patient desire 
for QOL by itself does not necessarily change therapeutic rec-
ommendations, because some therapies are documented to 
improve QOL. For example, meta-analyses published on nine 
randomized clinical trials assessing QOL with chemotherapy in 
NSCLC20,21 demonstrate that some components of QoL improve 
with chemotherapy, reflecting therapeutic efficacy.20,21 This is 
again consistent and accurately reflected in the survey results.
This on-line tool provided potential treatment choices 
for 96 different scenarios, without restriction to experts or par-
ticipants based on prognosis, cost or potential toxicity of each 
regimen. Thus, it is of interest that experts tended to select 
carboplatin over cisplatin in many scenarios, as seen in Figure 
1A and B. This is likely due to its more favorable toxicity pro-
file and ease of administration in these palliative settings. Two 
North American phase III trials have compared carboplatin 
plus paclitaxel with cisplatin-based combinations and demon-
strated similar efficacy but lower rates of nausea, leukopenia, 
and nephrotoxicity with the use of carboplatin22,23 in the first-
line treatment of patients with metastatic NSCLC. In addition, 
three meta-analyses have addressed the question of whether 
carboplatin based chemotherapy is as effective as cisplatin 
based,24–26 which collectively confirm that cisplatin based regi-
mens are associated with a slightly higher response rate than 
carboplatin regimens, with no definite survival difference.
Future iteration of the tool may be enhanced by includ-
ing brief comments from the expert panelists regarding their 
choices. This is currently not a part of the tool but has the 
potential to enhance its utility. For example, based on the large 
comparative Elderly Lung Cancer Vinorelbine Italian Study, 
vinorelbine as a single agent is effective in elderly patients with 
advanced NSCLC and is associated with improved survival and 
at least a trend toward improved QoL parameters compared with 
best supportive care alone.27 On the other hand, one can also 
justify using modified combination chemotherapy in the elderly 
population based on the chemotherapy French Intergroup study 
(IFCT-0501) to a combination of carboplatin plus paclitaxel 
or to single agent therapy with either gemcitabine or vinorel-
bine. Both overall survival and progression-free survival are 
significantly prolonged with combination chemotherapy com-
pared with single agent with therapy and overall generally 
well tolerated in both arms.28 Patients in the study were aged 
70 to 89 years and approximately 30% of these were PS 2. 
This demonstrated that chemotherapy can provide substantial 
clinical benefits, including improved overall survival, for older 
patients and those with Eastern Cooperative Oncology Group 
PS 2. Because guidelines have not been firmly established in the 
setting of PS2 patients does not mean that oncologists do not 
have to make day-to-day treatment decisions for this category 
of patients. In such situations, providing commentary from the 
expert panel regarding why certain choices were made may 
enhance the educational aspect of this tool.
Another enhancement of the on-line interactive tool 
could be citing direct evidence to support treatment deci-
sions in each case scenario. However, this tool was designed 
to incorporate expert opinion, not adherence to guidelines. As 
such, expert opinion is valuable both when direct evidence 
is not available and for interpretation of nuances not covered 
within guidelines. Other considerations to expand the utility 
of the on-line interactive tool include specifying parameters 
on restrictions for usage of certain drugs based on pre-exist-
ing end organ damage and providing potential risks associated 
with each treatment regimen, thus assisting participant physi-
cians in tailoring therapeutic decision-making.
In conclusion, our study shows the feasibility of utiliz-
ing an interactive on-line tool to assess practice patterns, to 
aid in therapeutic decision-making and to serve an educa-
tional mission by providing comparisons between practitio-
ner choices and those of an expert panel. To the best of our 
knowledge, this is the first study demonstrating quantitative 
variability in expert versus practicing physician using such 
an on-line interactive tool. Further studies utilizing such web-
based applications are warranted.
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